onc Videos

Videos

Patrick Tan, MD, PhD, Genome Institute of Singapore

Videos

New Strategies for Molecular Classification in Gastric Cancer

08/22/2023

Featuring Patrick Tan, MD, PhD

Featuring Patrick Tan, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on...

08/22/2023

Oncology

Monica Niger, MD, National Cancer Institute - MIlan

Videos

Clinical Relevance of BRAF Alterations in Biliary Tract Cancers

08/22/2023

Featuring Monica Niger, MD

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/22/2023

Oncology

Videos

Incorporating IDH and Menin Inhibitors as Therapies for Subsets of Patients With AML

08/22/2023

Featuring Amir Fathi, MD

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.

At the 2023 Great Debates &...

08/22/2023

Oncology

Videos

Evolving Frontline Therapies for Patients With Newly Diagnosed Multiple Myeloma

08/22/2023

Featuring Peter Voorhees, MD

Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Peter Voorhees, MD, discusses...

08/22/2023

Oncology

Videos

Outcomes of Patients Treated With Abatacept for the Prevention of GVHD

08/22/2023

Featuring Benjamin Watkins, MD

Featuring Benjamin Watkins, MD ...

Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.

Benjamin Watkins, MD, provides...

08/22/2023

Oncology

Videos

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

08/22/2023

Featuring Benjamin Watkins, MD

Featuring Benjamin Watkins, MD ...

Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.

Benjamin Watkins, MD, discusses...

08/22/2023

Oncology

Alfonso De Stefano, MD, PhD, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale

Videos

Intermittent vs Continuous Panitumumab Plus FOLFIRI for First-Line Treatment of Patients With RAS/BRAF Wild-Type Colorectal Cancer

08/21/2023

Featuring Alfonso De Stefano, MD, PhD

Featuring Alfonso De Stefano, MD, PhD...

At the 2023 World Congress on Gastrointestinal Cancers, Alfonso De Stefano, MD, PhD presented results of the IMPROVE study on intermittent or continuous panitumumab plus FOLFIRI for the first-line treatment of patients with RAS/BRAF wild-type...

At the 2023 World Congress on...

08/21/2023

Oncology

Eric Lander, MD, Vanderbilt University Medical Center

Videos

Tumor Mutational Signatures Among Patients With Early-Onset Versus Average-Onset Colorectal Cancer

08/21/2023

Featuring Eric Lander, MD

At the 2023 World Congress on Gastrointestinal Cancers, Eric Lander, MD, presents genomic clustering data suggesting that early-onset colorectal cancer may be caused by unique mutagenic processes compared to average-onset colorectal cancer.

At the 2023 World Congress on...

08/21/2023

Oncology

Antonella Cammarota, MD, Humanitas University

Videos

Impact of Prior Chemotherapy Administration on Intratumor Heterogeneity of CLDN18.2-Positive Gastroesophageal Cancers

08/21/2023

Featuring Antonella Cammarota, MD

Featuring Antonella Cammarota, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.

At the 2023 World Congress on...

08/21/2023

Oncology

Videos

FDA Approval of GPRC5D-Targeting Bispecific Antibody Talquetamab for Patients With R/R MM

08/21/2023

Featuring Ajai Chari, MD

Ajai Chari, MD, discusses the significance of the accelerated approval of talquetamab for the treatment of patients with R/R multiple myeloma, as well as offers advice for practicing oncologists regarding using this therapy.

Ajai Chari, MD, discusses the...

08/21/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology